Provided by Tiger Trade Technology Pte. Ltd.

KALA BIO

0.6901
-0.1220-15.02%
Post-market: 0.69020.0001+0.01%19:54 EDT
Volume:2.42M
Turnover:1.95M
Market Cap:13.35M
PE:-0.01
High:1.09
Open:0.8329
Low:0.5867
Close:0.8121
52wk High:1,030.00
52wk Low:0.5867
Shares:19.34M
Float Shares:18.59M
Volume Ratio:44.31
T/O Rate:13.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-72.4536
EPS(LYR):-165.5565
ROE:-345.32%
ROA:-65.43%
PB:1.48
PE(LYR):0.00

Loading ...

NASDAQ Trade Halt Volatility Trading Pause at 09:38 Am

Reuters
·
Aug 28

Kala Bio Faces NASDAQ Delisting After Stock Trades Below $1 for 30 Days

Reuters
·
Aug 28

Kala Bio Q2 EPS $(21.32) Up From $(85.64) YoY, Sales $0.00, Same YoY

Benzinga Earnings
·
Aug 20

Kala Bio Q2 Net Loss Narrows to $1.58 Million from Year-Ago $11.16 Million

Reuters
·
Aug 20

KALA BIO Announces Brief Delay in Quarterly Filing

TIPRANKS
·
Aug 15

Kala Bio Delays Q2 Form 10-Q Filing, Cites Added Time for Liquidity Disclosure

Reuters
·
Aug 14

Kala Bio Files ATM Offering of up to $250 Million in Common Stock - SEC Filing

Reuters
·
Jul 23

KALA BIO Files Atm Offering of up to $250.00 Mln in Common Stock - SEC Filing

THOMSON REUTERS
·
Jul 23

Kala Bio Q1 EPS $(0.14) Beats $(0.30) Estimate

Benzinga Earnings
·
May 16

Kala Bio Q1 FY26 net loss narrows to $1.62 million

Reuters
·
May 16

Kala Bio falls -21.7%

TIPRANKS
·
May 13

KALA BIO Inc - May Offer up to $350 Mln in Securities - SEC Filing

THOMSON REUTERS
·
May 08

Kala Bio to execute 1-for-50 reverse stock split May 8

Reuters
·
May 07

KALA BIO Inc - Announces 1-for-50 Reverse Stock Split

THOMSON REUTERS
·
May 07

Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments

GlobeNewswire
·
Apr 28

Kala Bio ‘celebrates’ U.S. Executive Order for psychedelic medicine

TIPRANKS
·
Apr 21

Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

GlobeNewswire
·
Apr 21

Kala Bio Q4 EPS $0.86 Beats $(1.44) Estimate, Sales $0.00

Benzinga Earnings
·
Apr 16

Kala Bio FY25 net loss narrows 30% to $27 million

Reuters
·
Apr 16

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

GlobeNewswire
·
Apr 01